Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T21:55:53.797Z.
Consensus retrieved: 2026-10-06T09:22:06.983Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T21:55:53.797Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b971b8577d60fbd13ce32004c11e36a47984c7f33f59c06b4987b60738766edb
Forward PE Ratio (N/A) = Dated Quote Price ($1.80) / Consensus Forward EPS ($-0.62)
FORWARD PE RATIO
N/A
Black Diamond Therapeutics, Inc.
Market Cap
$103.14M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | $103.14M | N/A |
| Anixa Biosciences, Inc. (ANIX)vs › | $102.75M | N/A |
| Definitive Healthcare Corp. (DH)vs › | $104.26M | 5.07 |
| Polaryx Therapeutics, Inc. Common Stock (PLYX)vs › | $104.68M | N/A |
| The Joint Corp. (JYNT)vs › | $101.36M | 29.63 |
| Immunic, Inc. (IMUX)vs › | $106.52M | N/A |
| OnKure Therapeutics, Inc. (OKUR)vs › | $99.62M | N/A |
| Vivani Medical, Inc. (VANI)vs › | $106.93M | N/A |
| Outlook Therapeutics, Inc. (OTLK)vs › | $106.96M | N/A |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.98M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.80, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.62 | $-0.81 – $-0.01 | 6 | n/m |
| 2027-12-31 | $-0.95 | $-1.62 – $-0.56 | 6 | n/m |
| 2028-12-31 | $-0.93 | $-1.18 – $-0.64 | 7 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
